Genomics finally expected to make significant contribution to clinical practice in near future.
Research and Markets announces the addition of this new report entitled "Clinical Genomics: The Impact of Genomic Technology on Clinical Trials and Medical Practice" to its offerings.
(PRWEB) March 27, 2004
Recent events suggest that genomics may finally be poised to make a significant contribution to clinical practice in the near future. In 2003, the Human Genome Project completed the sequence of all human genetic material, in addition to an essentially complete catalogue of all human genes. Since the practice of genomics relies on large-scale, comprehensive analyses of genes, this information will prove very valuable in speeding the implementation of genomics in clinical settings.
Furthermore, the U. S. federal government is emerging as a driving force for the adoption of genomics in clinical settings. In 2003, two major U. S. federal agencies issued reports indicating that implementation of genomics in the clinic is of high priority. The National Institutes of Health (NIH) issued a vision statement summarizing how genomics can contribute to the future of the practice of medicine. The U. S. Food and Drug Administration (FDA) issued draft guidelines for the submission of genomic data in drug applications, signifying a potentially pivotal change in the use of genomics in drug development.
The clinical genomics environment is ripe with opportunities for all players in the field—pharmaceutical companies, biotech firms, diagnostics manufacturers, tool suppliers, and researchers—as the NIH and FDA make it clear that increased use of genomics in the practice of medicine and drug development is both anticipated and encouraged. However, clinical genomics is far from widespread and still faces significant hurdles. Clinical Genomics: The Impact of Genomic Technology on Clinical Trials and Medical Practice examine the most important factors that will impact the transition towards more extensive adoption of genomics technologies in clinical trials and medical practice. This report offers critical strategic guidance to all companies participating in the application of genomics to the prediction, detection, and diagnosis, and treatment of disease.
Clinical Genomics: The Impact of Genomic Technology on Clinical Trials and Medical Practice assesses the challenges and future prospects for incorporating genomics technologies into standard clinical practice. The report examines some of the ways in which genomics could directly contribute to clinical practice, evaluates the scientific, technological, legal, and regulatory issues that will have a significant impact on the future adoption of genomics in clinical settings, and discusses the emerging business opportunities that will arise as the widespread application of genomics to clinical drug development, diagnostics, and medical practice comes to fruition.
Critical Issues in Clinical Genomics Are Presented in This New Study:
Clinical genomics applications for predicting a patient's response to drugs. The impact of new FDA guidelines on pharmacogenomics and the submission of genomic data. Biological, technological, economic, and sociological hurdles to incorporating genomics in the clinical setting.
For a complete index of this report click on http://www. researchandmarkets. com/reports/54521 (http://www. researchandmarkets. com/reports/54521)
About Research and Markets Ltd.
Research and Markets Ltd. are Europe's largest resource for market research. R&M distribute thousands of major research publications from the world's leading publishers, consultants and market analysts. R&M provide you with the latest forecasts on international and regional markets, key industries, the top companies, new products and the latest market trends.
For additional information on ResearchandMarkets. com, their range of reports or their value-added services, visit their web site at http://www. researchandmarkets. com (http://www. researchandmarkets. com) or mailto:press@researchandmarkets. com
